Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

Digital mental health technologies – a valuable tool in supporting people with depression and anxiety

January 29, 2026
Medical Communications MHRA, NHS, NICE, Wellcome, digital technologies, medical communications, mental health

The potential benefits of digital mental health technology for managing depression, anxiety and stress, together with other forms of care, …

Feature

Combination treatments: Takeda’s Implementation Framework and the broader landscape

September 23, 2025
Research and Development HIV/AIDS, Hepatology, NHS, NICE, Oncology, Takeda, combination therapy, oncology

Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment landscape and the impact of …

Feature

NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS

May 22, 2025
Market Access, Research and Development Haematology, Hympavzi, NHS, NICE, Pfizer, haemophilia B, marstacimab

Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care Excellence (NICE) has published final …

News
Press release

Dual immunotherapy for bowel cancer now available under NHS

April 23, 2025
Research and Development Bristol Myer Squibb, MHRA, NICE, Oncology, bowel cancer, colorectal cancer, immunotherapy

Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in the UK by the Medicines …

News

Takeda announces launch of Framework to help support patient access to life-extending combination treatments

February 25, 2025
Business Services Cancer, HIV/AIDS, Immunology, NHS, NICE, Oncology, Takeda, VPAG, patient access

The Conceptual Implementation Framework outlines critical points within the UK healthcare access ecosystem to help improve the introduction of combination …

News
Press release

NICE recommendation for KORSERDU®▼ (elacestrant) marks ‘step-change’ in the treatment of ESR1-mutated metastatic breast cancer

December 19, 2024
ESR1, Menari Group, NICE, breast cancer, drug

Elacestrant is the first tailored treatment for certain people with oestrogen receptor (ER)-positive HER2-negative locally advanced and metastatic breast cancer …

News
Press release

NICE RECOMMENDS LILLY’S TIRZEPATIDE (MOUNJARO ®▼) FOR MANAGING OVERWEIGHT AND OBESITY IN FINAL DRAFT GUIDANCE

December 10, 2024
Mounjaro, NICE, lilly, weight-loss

BASINGSTOKE, 5th December 2024 – Eli Lilly and Company announced today that the National Institute for Health and Care Excellence …

News
Press release
bowel_cancer_screening

The National Institute for Health and Care Excellence announce technology appraisal guidance recommending risankizumab for adult patients with moderate to severe ulcerative colitis

August 29, 2024
Research and Development AbbVie, Crohns, Gastrointestinal tract, Immunology, NICE, approval, ulcerative colitis

The National Institute for Health and Care Excellence (NICE) have recommended adult patients in England or Wales with moderately or …

News

NICE recommends digital tech for ADHD diagnosis in children and young people

July 16, 2024
Medical Communications ADHD, Diagnostics, NICE

The National Institute for Health and Care Excellence (NICE) has announced that its diagnostics advisory committee has recommended the QbTest …

News

NICE recommends migraine treatment for NHS use

April 11, 2024
Medical Communications NHS, NICE, Neurology, migraine

The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s Aquipta (atogepant) as an option …

News

GSK’s Jemperli recommended by NICE for endometrial cancer treatment

March 5, 2024
Medical Communications GSK, Jemperli, NICE, Oncology, endometrial cancer

GSK has announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of Jemperli (dostarlimab) …

News

NICE recommends SC treatment of AbbVie’s Tepkinly for patients with DLBCL

February 1, 2024
Medical Communications AbbVie, DLBCL, NICE, Oncology, lymphoma

AbbVie has announced that the National Institute for Health and Care Excellence (NICE) has recommended Tepkinly (epcoritamab) as a treatment …

News

NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19

January 12, 2024
Medical Communications COVID-19, Infections and infestations, NICE

The National Institute for Health and Care Excellence (NICE) has announced that it has expanded the guidance around which patients …

News

Novo Nordisk launches Wegovy in the UK

September 4, 2023
Medical Communications NHS, NICE, Novo Nordisk, Obesity, Wegovy, weight loss

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK through a controlled and limited …

News

Amicus Therapeutics’ Pompe disease treatment approved for use in UK

August 17, 2023
Medical Communications Amicus Therapeutics, MHRA, NICE, Pompe disease, Rare Diseases

Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorisation …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026